Printer Friendly

Ciba forms development agreement with Biosignal.

Ciba Specialty Chemicals, Basel, Switzerland, has announced the creation of a joint development and licensing agreement with Biosignal Ltd., Sydney, Australia, to develop novel antimicrobial compounds for consumer and industrial products based upon Biosignal's anti-biofilm technology. As part of the agreement, Biosignal has granted Ciba Specialty Chemicals an exclusive license in some of Ciba's key markets including plastics, coatings, paints, fibers, and paper products.

Biosignal's anti-biofilm technology is based on a discovery that the eastern Australian seaweed Delisea pulchra produces natural furanones that disable bacteria's ability to colonize.

Development was expected to begin in May and testing will occur at Ciba's laboratories in Basel and Biosignal's facilities in Sydney.
COPYRIGHT 2006 Federation of Societies for Coatings Technology
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Business & Industry
Publication:JCT CoatingsTech
Date:Jun 1, 2006
Words:109
Previous Article:Akzo Nobel makes bid for Sico Inc.
Next Article:Smithers Group acquires Rapra Technology.


Related Articles
Ciba Specialty Chemicals.
Ciba specialty chemicals adds European distributors. (Contracts, Licenses).
Ciba & Techmer cooperate in masterbatches.
Ciba commits marketing dollars.
Ciba buys Raisio Chemicals.
BIOSIGNAL/IER REPORT 100% ANTI-BACTERIAL EFFICACY OF LENSES.
BIOSIGNAL AWARDED $1.377 M FOR ANTI-BACTERIAL CONTACT LENSES.
New UQTR chair funded by Ciba.
Ciba in agreement with Biosignal.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters